Highlights of This Issue 2409

SMALL MOLECULE THERAPEUTICS

2411 Targeting Ribonucleotide Reductase M2 and NF-κB Activation with Didox to Circumvent Tamoxifen Resistance in Breast Cancer
Khyati N. Shah, Elizabeth A. Wilson, Ritu Malla, Howard L. Ellord, and Jesika S. Faridi

2422 HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors
David A. Proia, Donald L. Smith, Junyi Zhang, John-Paul Jimenez, Jim Sang, Luisa Chin Ogawa, Manuel Sequeira, Noriaki Tatsuta, Sami Osman, Richard C. Bates, Dinesh Chimmanamada, and Weiwen Ying

2433 Inhibition of ABCB1 Overcomes Cancer Stem Cell–like Properties and Acquired Resistance to MET Inhibitors in Non–Small Cell Lung Cancer
Teppei Sugano, Masahiro Seike, Rintaro Noro, Chie Soeno, Mika Chiba, Fenfei Zou, Shinji Nakamichi, Nobuhiko Nishijima, Masaru Matsumoto, Akihiko Miyanaga, Kaoru Kubota, and Akihiko Gemma

2441 Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors
Barry R. Davies, Nin Guan, Armelle Logie, Claire Crafter, Lyndsey Hanson, Vivien Jacobs, Neil James, Philippa Dudley, Kelly Jacques, Brendon Ladd, Celina M. D’Cruz, Michael Zinda, Justin Lindemann, Makoto Koidaira, Kenji Tamura, and Emma L. Jenkins

2452 Sarcoma Cell Line Screen of Oncology Drugs and Investigational Agents Identifies Patterns Associated with Gene and microRNA Expression
Beverly A. Teicher, Eric Polley, Mark Kunkel, David Evans, Thomas Silvers, Rene Delosh, Julie Lautman, Chad Ogle, Russell Reinhart, Michael Selby, John Connelly, Erik Harris, Anne Monks, and Joel Morris

2463 A Novel Eg5 Inhibitor (LY2523355) Causes Mitotic Arrest and Apoptosis in Cancer Cells and Shows Potent Antitumor Activity in Xenograft Tumor Models
Xiang Y. Ye, Li Fan, Robert D. Van Horn, Ryuichiro Nakai, Yoshihisa Ohta, Shino Akinaga, Chikara Murakata, Yoshinori Yamashita, Tinggui Yin, Kelly M. Credille, Gregory P. Donoho, Farhana F. Merzouq, Heng Li, Amit Aggarwal, Kerry Blanchard, and Eric H. Westin

2473 CXCR4 Protein Epitope Mimetic Antagonist POL5551 Disrupts Metastasis and Enhances Chemotherapy Effect in Triple-Negative Breast Cancer
Jingyu Xiang, Michelle A. Hurchla, Francesca Fontana, Xinning Su, Sarah R. Amend, Alison K. Isser, Garry J. Douglas, Chidananda Mudalagiri, Kathryn E. Luker, Timothy Pluard, Foluso O. Ademuyiwa, Barbara Romagnoli, Gerald Tuffin, Eric Chevalier, Gary D. Luker, Michael Bauer, Johann Zimmermann, Rebecca L. Afi, Klaus Dembowsky, and Katherine N. Weilbaecher

2486 A Novel Inhibitor of AKT1–PDPK1 Interaction Efficiently Suppresses the Activity of AKT Pathway and Restricts Tumor Growth In Vivo
Kristina Mäemets-Allas, Janeli Viil, and Viljar Jaks

2497 Identification of Novel Ezrin Inhibitors Targeting Metastatic Osteosarcoma by Screening Open Access Malaria Box
Haydar Çelik, Sung-Hyeok Hong, Daisy D. Colón-López, Jenny Han, Yasemin Saygiydeg Kont, Tsion Z. Minas, Matthew Swift, Mitkell Paige, Eric Glasgow, Jeffrey A. Toretsky, Jürgen Bosch, and Aykut Üren

2508 AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules
Tumor MET Expression and Gene Amplification in Chinese Patients with Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer
Zhi Peng, Zhongwu Li, Jing Gao, Ming Lu, Jifang Gong, En-Tzu Tang, Kelly S. Oliner, Yong-Jiang Hei, Hui Zhou, and Lin Shen

Seribantumab, an Anti-ERBB3 Antibody, Delays the Onset of Resistance and Restores Sensitivity to Letrozole in an Estrogen Receptor–Positive Breast Cancer Model

MiRNA-203 Reduces Nasopharyngeal Carcinoma Radioresistance by Targeting IL8/AKT Signaling
Jia-Quan Qu, Hong-Mei Yi, Xu Ye, Jin-Feng Zhu, Hong Yi, Li-Na Li, Ta Xiao, Li Yuan, Jiao-Yang Li, Yuan-Yuan Wang, Juan Feng, Qu-Yan He, Shan-Shan Lu, and Zhi-Qiang Xiao

A Novel Fully Humanized 3D Skin Equivalent to Model Early Melanoma Invasion

ABOUT THE COVER

Early-stage cutaneous melanoma development is characterized by uncontrolled proliferation and invasion of melanoma cells from the epidermis into the dermis through the basement membrane. This process is modelled using a novel full-thickness human melanoma skin equivalent in which melanoma cells form nests at the epidermal/dermal junction, as seen in this image, the basement membrane component type IV collagen, before disrupting the basement membrane structure as they invade at later time points. For full details of this model and its use for the investigation of early melanoma invasion, see the article by Hill and colleagues on page 2665.
Molecular Cancer Therapeutics

14 (11)

Mol Cancer Ther 2015;14:2409-2673.

Updated version
Access the most recent version of this article at:
http://mct.aacrjournals.org/content/14/11

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.